Search research articles
Contact Us
Filters
Showing results (21-30 of 46) with videos related to
Page
of 5
Sort By:
Oncology and Therapy
|
July 7, 2017
Efficacy and Safety Results of the Afatinib Expanded Access Program
Edward S Kim, Balazs Halmos, Ingrid F Kohut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099
Thomas J Lynch, Taral Patel, Luke Dreisbach, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 15, 2014
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS)
Fairooz Kabbinavar, Louis Fehrenbacher, John Hainsworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2008
Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer
Shannon Puhalla, Ewa Mrozek, Donn Young, et al.
Coronary Artery Disease
|
December 4, 2008
Stress-induced ST-segment deviation in relation to the presence and severity of coronary artery disease in patients with normal myocardial perfusion imaging
Jonathan W Weinsaft, Shant J Manoushagian, Taral Patel, et al.
Journal of Cardiovascular Electrophysiology
|
June 16, 2012
Prevalence and predictors of cable extrusion and loss of electrical integrity with the Riata defibrillator lead
Sharon Shen, Prashant Bhave, Evan Giedrimas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
Bruce E Johnson, Fairooz Kabbinavar, Louis Fehrenbacher, et al.
Journal of the Society for Cardiovascular Angiography & Interventions
|
March 10, 2025
Novel Mechanical Aspiration Thrombectomy in Patients With Acute Pulmonary Embolism: Results From the Prospective APEX-AV Trial
Mona Ranade, Malcolm T Foster, Paul S Brady, et al.
Future Oncology (London, England)
|
June 30, 2026
Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia
Jing-Zhou Hou, Rushir Choksi, Gregory A Maglinte, et al.
Anti-Cancer Drugs
|
August 24, 2013
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel
Javier Cortés, Sandra M Swain, Iveta Kudaba, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 46) with videos related to
Sort By:
Page
of 5
Oncology and Therapy
|
July 7, 2017
Efficacy and Safety Results of the Afatinib Expanded Access Program
Edward S Kim, Balazs Halmos, Ingrid F Kohut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099
Thomas J Lynch, Taral Patel, Luke Dreisbach, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 15, 2014
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS)
Fairooz Kabbinavar, Louis Fehrenbacher, John Hainsworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2008
Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer
Shannon Puhalla, Ewa Mrozek, Donn Young, et al.
Coronary Artery Disease
|
December 4, 2008
Stress-induced ST-segment deviation in relation to the presence and severity of coronary artery disease in patients with normal myocardial perfusion imaging
Jonathan W Weinsaft, Shant J Manoushagian, Taral Patel, et al.
Journal of Cardiovascular Electrophysiology
|
June 16, 2012
Prevalence and predictors of cable extrusion and loss of electrical integrity with the Riata defibrillator lead
Sharon Shen, Prashant Bhave, Evan Giedrimas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
Bruce E Johnson, Fairooz Kabbinavar, Louis Fehrenbacher, et al.
Journal of the Society for Cardiovascular Angiography & Interventions
|
March 10, 2025
Novel Mechanical Aspiration Thrombectomy in Patients With Acute Pulmonary Embolism: Results From the Prospective APEX-AV Trial
Mona Ranade, Malcolm T Foster, Paul S Brady, et al.
Future Oncology (London, England)
|
June 30, 2026
Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia
Jing-Zhou Hou, Rushir Choksi, Gregory A Maglinte, et al.
Anti-Cancer Drugs
|
August 24, 2013
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel
Javier Cortés, Sandra M Swain, Iveta Kudaba, et al.
Page
of 5